Tacrolimus (Tac) is widely used for the prevention of rejection after solid organ
transplantation. Finding the optimal balance between effective Tac concentrations and …

ABSTRACT Introduction: Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy
after solid organ transplantation and will probably remain so. Excluding belatacept, no new …

Short-term patient and graft outcomes continue to improve after kidney and liver
transplantation, with 1-year survival rates over 80%; however, improving longer-term …

Background Lack of adherence to immunosuppressive drugs is a risk factor for development
of de novo donor-specific antibodies (dnDSA) and can contribute to antibody-mediated …

Wide variations in tacrolimus levels have been identified as a risk factor for inferior kidney
allograft survival but past studies have not properly accounted for the dynamic nature of drug …

Tacrolimus is a critical dose drug with a considerable intrapatient variability (IPV) in its
pharmacokinetics. We investigated whether a high IPV in tacrolimus exposure is associated …

Pediatric heart transplantation is standard of care for children with end-stage heart failure.
The diverse age range, diagnoses, and practice variations continue to challenge the …

The purpose of this study was to determine the intrapatient (within the same patient)
variability of tacrolimus in adherent patients. Daily tacrolimus trough levels were obtained at …

Nonadherence to immunosuppressant medications is a leading cause of poor long-term
outcomes in transplant recipients. The Medication Level Variability Index (MLVI) provides a …

High intrapatient variability (IPV) of tacrolimus concentrations is increasingly recognized as
a predictor of poor outcome in solid organ recipients. How it relates to evolution of histology …